• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Mixed; Li Auto Shares Plummet After Q1 Results

    5/20/24 9:57:00 AM ET
    $AKTS
    $GTBP
    $JAGX
    $LI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTS alert in real time by email

    U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 0.5% on Monday.

    Following the market opening Monday, the Dow traded down 0.19% to 39,925.91 while the NASDAQ rose 0.50% to 16,769.45. The S&P 500 also rose, gaining, 0.19% to 5,313.25.

    Check This Out: Top 3 Financial Stocks That Are Set To Fly This Quarter

    Leading and Lagging Sectors

    Information technology shares rose by 0.9% on Monday.

    In trading on Monday, real estate shares fell by 0.6%.

    Top Headline

    Shares of Li Auto Inc (NASDAQ:LI) dipped more than 14% on Monday after the company reported fiscal first-quarter 2024 results.

    The company posted revenue growth of 36.4% year-on-year to $3.55 billion, missing the analyst consensus estimate of $3.84 billion. Adjusted net earnings per ADS was 17 cents missed the analyst consensus estimate of 35 cents.

    Equities Trading UP
                           

    • GT Biopharma, Inc. (NASDAQ:GTBP) shares shot up 142% to $7.54. GT Biopharma, last week, posted a narrower-than-expected quarterly loss.
    • Shares of Tantech Holdings Ltd (NASDAQ:TANH) got a boost, surging 119% to $1.44.
    • MultiMetaVerse Holdings Limited (NASDAQ:MMV) shares were also up, gaining 102% to $1.25. MultiMetaVerse Holdings signed a non-binding term sheet to acquire 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries.

    Equities Trading DOWN

    • Virios Therapeutics, Inc. (NASDAQ:VIRI) shares dropped 49% to $0.1790 after the company priced a $1.7 million pubic offering of 8.5 million shares of common stock at $0.20 per share.
    • Shares of Akoustis Technologies, Inc. (NASDAQ:AKTS) were down 47% to $0.1899 after Qorvo won a jury verdict against the company in a trade secret misappropriation and patent infringement case.
    • Jaguar Health, Inc (NASDAQ:JAGX) was down, falling 44% to $0.1457 after the company announced a 1-for-60 reverse stock split.

    Also Check This Out: This Analyst With 85% Accuracy Rate Sees Around 8% Upside In NVIDIA – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts

    Commodities

    In commodity news, oil traded down 0.4% to $79.74 while gold traded up 0.8% at $2,436.90.

    Silver traded up 1.9% to $31.84 on Monday, while copper rose 0.7% to $5.0860.

    Euro zone

    European shares were higher today. The eurozone's STOXX 600 gained 0.2%, Germany's DAX rose 0.4% and France's CAC 40 climbed 0.5%. Spain's IBEX 35 Index rose 0.2%, while London's FTSE 100 rose 0.3%.

    Spain’s consumer confidence indicator climbed to 84.5 in April compared to 82.5 in March. The construction output in Italy rose by 3.8% year-over-year in March.

    Asia Pacific Markets

    Asian markets closed higher on Monday, with Japan's Nikkei gaining 0.73%, China's Composite Index climbing 0.54%, Hong Kong's Hang Seng Index gaining 0.42% and India's S&P BSE Sensex gaining 0.46%.

    Hong Kong's unemployment rate came in unchanged at 3% in the three months ending April 2024. Malaysia’s trade surplus shrank to MYR 7.7 billion in April from MYR 12.6 billion in the year-ago month. The People’s Bank of China held key lending rates at the recent fixing.

    Economics

    No major economic reports will be released today.

    Now Read This: Insiders Buying Sempra And 2 Other Stocks

    Get the next $AKTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTS
    $GTBP
    $JAGX
    $LI

    CompanyDatePrice TargetRatingAnalyst
    Li Auto Inc.
    $LI
    2/9/2026$14.00Neutral → Underweight
    Analyst
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$30.00Overweight
    Analyst
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$34.00Buy
    BofA Securities
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$31.00Outperform
    Leerink Partners
    Aktis Oncology Inc.
    $AKTS
    2/3/2026Buy
    TD Cowen
    Li Auto Inc.
    $LI
    1/23/2026$17.50Buy → Hold
    Jefferies
    Li Auto Inc.
    $LI
    12/4/2025$18.60Buy → Hold
    HSBC Securities
    Li Auto Inc.
    $LI
    12/1/2025$18.50Buy → Hold
    China Renaissance
    More analyst ratings

    $AKTS
    $GTBP
    $JAGX
    $LI
    SEC Filings

    View All

    SEC Form 6-K filed by Li Auto Inc.

    6-K - Li Auto Inc. (0001791706) (Filer)

    2/27/26 4:02:05 PM ET
    $LI
    Auto Manufacturing
    Industrials

    SEC Form 6-K filed by Li Auto Inc.

    6-K - Li Auto Inc. (0001791706) (Filer)

    2/27/26 4:01:46 PM ET
    $LI
    Auto Manufacturing
    Industrials

    Jaguar Health Inc. filed SEC Form 8-K: Other Events, Material Modification to Rights of Security Holders, Regulation FD Disclosure

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    2/18/26 9:01:37 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $GTBP
    $JAGX
    $LI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer King Steven R. was granted 11,740 shares, increasing direct ownership by 8,097% to 11,885 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    1/21/26 4:30:46 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Conte Lisa A was granted 28,592 shares, increasing direct ownership by 4,293% to 29,258 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    1/21/26 4:30:40 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Wolin Jonathan S. was granted 11,740 shares, increasing direct ownership by 5,929% to 11,938 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    1/21/26 4:30:27 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $GTBP
    $JAGX
    $LI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Li Auto Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    BEIJING, China, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:LI, HKEX: 2015)), a leader in China's new energy vehicle market, today announced that it will report its unaudited financial results for the fourth quarter and full year 2025 before the U.S. market opens on Thursday, March 12, 2026. The Company's management will hold an earnings conference call on Thursday, March 12, 2026, at 8:00 A.M. U.S. Eastern Time or 8:00 P.M. Beijing/Hong Kong Time on the same day. For participants who wish to join the call, please complete online registration using the link provided below prior to the scheduled call start time. Upon registration, participants will

    2/27/26 4:00:00 AM ET
    $LI
    Auto Manufacturing
    Industrials

    Aktis Oncology to Present at Upcoming March Investor Conferences

    BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference Date & Time: Tuesday, March 3, 2026, at 1:10 p.m. ETLocation: Boston, MA Leerink Partners Global Healthcare ConferenceDate & Time: Monday, March 9, 2026, at 1:40 p.m. ETLocation: Miami, FL A live w

    2/24/26 4:05:00 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

    U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b trial of AKY-1189 enrolling patients with locally advanced or metastatic urothelial cancer and several other Nectin-4 expressing tumor types BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that the U.S. Food and Drug Administ

    2/24/26 8:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $GTBP
    $JAGX
    $LI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:20:21 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:19:26 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gadicke Ansbert converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:17:54 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $GTBP
    $JAGX
    $LI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Li Auto downgraded by Analyst with a new price target

    Analyst downgraded Li Auto from Neutral to Underweight and set a new price target of $14.00

    2/9/26 7:00:29 AM ET
    $LI
    Auto Manufacturing
    Industrials

    Analyst initiated coverage on Aktis Oncology with a new price target

    Analyst initiated coverage of Aktis Oncology with a rating of Overweight and set a new price target of $30.00

    2/3/26 6:54:43 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Aktis Oncology with a new price target

    BofA Securities initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $34.00

    2/3/26 6:54:33 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $GTBP
    $JAGX
    $LI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tantech Holdings Ltd.

    SC 13G/A - TANTECH HOLDINGS LTD (0001588084) (Subject)

    11/13/24 11:17:41 AM ET
    $TANH
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Akoustis Technologies Inc.

    SC 13G/A - Akoustis Technologies, Inc. (0001584754) (Subject)

    11/12/24 1:34:05 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tantech Holdings Ltd.

    SC 13G/A - TANTECH HOLDINGS LTD (0001588084) (Subject)

    11/6/24 4:30:13 PM ET
    $TANH
    Major Chemicals
    Industrials

    $AKTS
    $GTBP
    $JAGX
    $LI
    Financials

    Live finance-specific insights

    View All

    Li Auto Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    BEIJING, China, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:LI, HKEX: 2015)), a leader in China's new energy vehicle market, today announced that it will report its unaudited financial results for the fourth quarter and full year 2025 before the U.S. market opens on Thursday, March 12, 2026. The Company's management will hold an earnings conference call on Thursday, March 12, 2026, at 8:00 A.M. U.S. Eastern Time or 8:00 P.M. Beijing/Hong Kong Time on the same day. For participants who wish to join the call, please complete online registration using the link provided below prior to the scheduled call start time. Upon registration, participants will

    2/27/26 4:00:00 AM ET
    $LI
    Auto Manufacturing
    Industrials

    Li Auto Inc. Announces Unaudited Third Quarter 2025 Financial Results

    Quarterly total revenues reached RMB27.4 billion (US$3.8 billion)1Quarterly deliveries reached 93,211 vehicles BEIJING, China, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:LI, HKEX: 2015)), a leader in China's new energy vehicle market, today announced its unaudited financial results for the quarter ended September 30, 2025. Operating Highlights for the Third Quarter of 2025 Total deliveries for the third quarter of 2025 were 93,211 vehicles, representing a 39.0% year-over-year decrease.   2025 Q3 2025 Q2 2025 Q1 2024 Q4 Deliveries 93,211 111,074 92,864 158,696             2024 Q3 2024 Q2 2024 Q1 2023 Q4 Deliveries 152,831 108,581 80,400 131,805   

    11/26/25 3:45:00 AM ET
    $LI
    Auto Manufacturing
    Industrials

    Li Auto Inc. to Report Third Quarter 2025 Financial Results on November 26, 2025

    BEIJING, China, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:LI, HKEX: 2015)), a leader in China's new energy vehicle market, today announced that it will report its unaudited financial results for the third quarter of 2025 before the U.S. market opens on Wednesday, November 26, 2025. The Company's management will hold an earnings conference call on Wednesday, November 26, 2025, at 7:00 A.M. U.S. Eastern Time or 8:00 P.M. Beijing/Hong Kong Time on the same day. For participants who wish to join the call, please complete online registration using the link provided below prior to the scheduled call start time. Upon registration, participants will rece

    11/14/25 3:30:00 AM ET
    $LI
    Auto Manufacturing
    Industrials

    $AKTS
    $GTBP
    $JAGX
    $LI
    Leadership Updates

    Live Leadership Updates

    View All

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    GT Biopharma Appoints New Member to its Board of Directors

    SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors. "We are very pleased to welcome David to the Board of Directors. David is an experienced senior executive with global connections and a proven track record of success in working with corporate management teams," said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. "His guidance and perspective will be

    6/13/25 9:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Appoints New Member to its Board of Directors

    SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position. "We are delighted to welcome Hilary to the Board of Directors at this exciting time, and we look forward to leveraging her expertise as we continue to make great clinical progress with our NK engagers," said Michael Breen, Executive Chairman a

    5/14/25 7:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care